Quandongboy,
So the latest PR is great news even though we have known the following since 2004:
BioCurex to Present its RECAF Blood Test results at International Cancer Congress.
RICHMOND, British Columbia, May 17th 2004. -- BioCurex Inc. (BOCX.PK - News is pleased to announce that the ISOBM 2004 Scientific Committee has reviewed and accepted all five abstracts submitted by Dr. Moro and his scientific team on BioCurex’s patent protected technologies.
The abstracts report the results obtained with BioCurex’s Serum-RECAF(TM) blood test for Ovarian, Breast, Stomach and Lung cancers. Overall, the cancer detection sensitivity reported was in the vicinity of 90% with slightly over 95% specificity. The aggregate number of cancer patients was 175 and normal donors were 353.
The Lung cancer presentation also includes results using the Company’s Histo-RECAF(TM) cancer cell staining kit: Briefly, 22 out of 24 lung cancers were stained positively. Dr. Moro will also present a 5th abstract describing RECAF’s basic scientific background.
The scientific posters will be displayed June 22nd 2004 and the abstracts are to be published in a supplementary issue of the scientific journal “Tumor Biology”.
--------
-But now 5 years later, we are supposed to be excited that Recaf can limit false positives for Ovarian Cancer?
Hopefully you and Half are correct that this PR is just a hint of great things to come in commercializing tests for ovarian and colon cancer using Recaf, but I am skeptical.
mcd
